title: Is the aggressive management of hyperlipidemia in nephrotic syndrome mandatory?
abstract: The development of the nephrotic syndrome is associated with a lipid profile characterized by increased total and low density lipoprotein cholesterol. Although total high density lipoprotein (HDL) values may be in the normal range, there is frequently abnormalities of HDL subclasses, with reduction of the mature HDL2 subfraction. While these lipid changes may be considered a risk for atherosclerosis, they revert to normal with remission of the nephrotic syndrome. However, with chronic nephrotic range proteinuria, these abnormalities persist and may also be associated with increased levels of lipoprotein (a), increased levels of very light density lipoprotein and further reductions in HDL. These factors could all contribute to greater risk for atherosclerosis. Although coronary artery disease is frequently seen in patients with end-stage renal disease, and many uncontrolled studies in patients with chronic nephrotic syndrome have suggested an increased prevalence of cardiovascular disease, no prospective studies to evaluate relationship between lipid abnormalities and cardiac disease have been performed in patients with the nephrotic syndrome. Recent experimental data have also suggested a relationship between hyperlipidemia and progressive renal injury. Unfortunately, human epidemiological data are incomplete in correlating lipid changes with renal disease in patients with chronic nephrotic syndrome. No therapeutic trials have tested whether or not pharmacologic interventions will benefit either the cardiac or renal disease that ensues in patients with chronic persistent nephrotic syndrome. Thus, considerably more data are needed to help clarify this important area.
authors.affiliation: Department of Medicine, Hennepin County Medical Center, University of Minnesota, Minneapolis.
authors.forename: W F
authors.initials: WF
authors.lastname: Keane
authors.forename: J V
authors.initials: JV
authors.lastname: St Peter
authors.forename: B L
authors.initials: BL
authors.lastname: Kasiske
mesh_terms: D002318:Cardiovascular Diseases / Q000209:etiology; D006801:Humans; D006949:Hyperlipidemias / Q000209:etiology / Q000628:therapy*; D008055:Lipids / Q000097:blood; D008074:Lipoproteins / Q000097:blood; D009404:Nephrotic Syndrome / Q000150:complications*
chemical_list: D008055:Lipids; D008074:Lipoproteins